Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 13/20 | 0.41 |
| ▸ | NOS3 | P29474 | 10/20 | 0.41 |
| ▸ | NOS2 | P35228 | 8/20 | 0.41 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.33 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7073279 | 0.96 | NOS3 (0.38) | NOS1NOS3NOS2ALOX5APFEN1 | |
| SCHEMBL220602 | 0.82 | NOS1 (0.46) | NOS1NOS3NOS2IDH1 | |
| SCHEMBL251144 | 0.78 | NOS1 (0.42) | NOS1NOS3NOS2ALOX5APFEN1 | |
| SCHEMBL6584706 | 0.75 | NOS1 (0.64) | NOS1NOS3NOS2 | |
| SCHEMBL958697 | 0.73 | NOS1 (0.57) | NOS1NOS3NOS2 | |
| SCHEMBL6583994 | 0.72 | NOS3 (0.41) | NOS1NOS3NOS2IDH1ALOX5AP | |
| SCHEMBL6585159 | 0.72 | NOS1 (0.59) | NOS1NOS3NOS2ALOX5APFEN1 | |
| SCHEMBL6584246 | 0.72 | NOS1 (0.59) | NOS1NOS3NOS2ALOX5APFEN1 | |
| SCHEMBL6584972 | 0.70 | NOS3 (0.62) | NOS1NOS3NOS2CNR2 | |
| SCHEMBL956120 | 0.69 | NOS1 (0.53) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | PFIZER INC. | 2003-08-28 | — | — | US | disclosed |
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | PFIZER INC. | 2001-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010007873-A1 | Compounds such as 4-(6-amino-pyridin-2-yl)-3-methoxyphenol as nitric oxide synthase inhibitors used to treat central nervous system disorders, inflammatory disorders, septic shock, etc... | NOS1, PTGS1, NOS2 | NOS1 1/4885NOS3 4/4885NOS2 3/4885 |
| US-20030162765-A1 | Use in treatment and prevention of central nervous system and other disorders | GRIN2C, GRIN2A, CNR2 | NOS1 2484/4885NOS3 2496/4885NOS2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.